Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-Infected children

Ahmed Hamed Salem, Courtney V Fletcher, Richard C. Brundage

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aim of this analysis was to create a pharmacometric model of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. The data consisted of 3,172 plasma concentrations from 96 HIV-1-infected children who participated in the Pediatric AIDS Clinical Trials Group 382 (PACTG382) study. Analyses were performed using NONMEM, and the impacts of body weight, age, race, sex, formulation, liver function, and cytochrome P450 2B6 (CYP2B6)-G516T and multidrugresistance transporter gene (MDR1)-C3435T polymorphisms were assessed. A one-compartment model using weight-based allometry on oral clearance and apparent volume of distribution adequately described the data. A sigmoid maximum-effect (Emax) maturation model demonstrated an increase in oral clearance with age to reach 90% of its mature level by the age of 9 months. The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90% of its mature value by the age of 8 years. The CYP2B6-G516T polymorphism decreased oral clearance, while the MDR1-C3435T polymorphism demonstrated no effect.

Original languageEnglish (US)
Pages (from-to)136-143
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

efavirenz
Pharmacogenetics
Pharmacokinetics
HIV
Sigmoid Colon
Biological Availability
Capsules
HIV-1
Acquired Immunodeficiency Syndrome
Body Weight
Clinical Trials
Pediatrics
Weights and Measures
Liver
Genes
Cytochrome P-450 CYP2B6

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-Infected children. / Salem, Ahmed Hamed; Fletcher, Courtney V; Brundage, Richard C.

In: Antimicrobial Agents and Chemotherapy, Vol. 58, No. 1, 01.01.2014, p. 136-143.

Research output: Contribution to journalArticle

@article{b6d4ee7e6b9f414e8323dc148e4415d3,
title = "Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-Infected children",
abstract = "The aim of this analysis was to create a pharmacometric model of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. The data consisted of 3,172 plasma concentrations from 96 HIV-1-infected children who participated in the Pediatric AIDS Clinical Trials Group 382 (PACTG382) study. Analyses were performed using NONMEM, and the impacts of body weight, age, race, sex, formulation, liver function, and cytochrome P450 2B6 (CYP2B6)-G516T and multidrugresistance transporter gene (MDR1)-C3435T polymorphisms were assessed. A one-compartment model using weight-based allometry on oral clearance and apparent volume of distribution adequately described the data. A sigmoid maximum-effect (Emax) maturation model demonstrated an increase in oral clearance with age to reach 90{\%} of its mature level by the age of 9 months. The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90{\%} of its mature value by the age of 8 years. The CYP2B6-G516T polymorphism decreased oral clearance, while the MDR1-C3435T polymorphism demonstrated no effect.",
author = "Salem, {Ahmed Hamed} and Fletcher, {Courtney V} and Brundage, {Richard C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.01738-13",
language = "English (US)",
volume = "58",
pages = "136--143",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-Infected children

AU - Salem, Ahmed Hamed

AU - Fletcher, Courtney V

AU - Brundage, Richard C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of this analysis was to create a pharmacometric model of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. The data consisted of 3,172 plasma concentrations from 96 HIV-1-infected children who participated in the Pediatric AIDS Clinical Trials Group 382 (PACTG382) study. Analyses were performed using NONMEM, and the impacts of body weight, age, race, sex, formulation, liver function, and cytochrome P450 2B6 (CYP2B6)-G516T and multidrugresistance transporter gene (MDR1)-C3435T polymorphisms were assessed. A one-compartment model using weight-based allometry on oral clearance and apparent volume of distribution adequately described the data. A sigmoid maximum-effect (Emax) maturation model demonstrated an increase in oral clearance with age to reach 90% of its mature level by the age of 9 months. The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90% of its mature value by the age of 8 years. The CYP2B6-G516T polymorphism decreased oral clearance, while the MDR1-C3435T polymorphism demonstrated no effect.

AB - The aim of this analysis was to create a pharmacometric model of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. The data consisted of 3,172 plasma concentrations from 96 HIV-1-infected children who participated in the Pediatric AIDS Clinical Trials Group 382 (PACTG382) study. Analyses were performed using NONMEM, and the impacts of body weight, age, race, sex, formulation, liver function, and cytochrome P450 2B6 (CYP2B6)-G516T and multidrugresistance transporter gene (MDR1)-C3435T polymorphisms were assessed. A one-compartment model using weight-based allometry on oral clearance and apparent volume of distribution adequately described the data. A sigmoid maximum-effect (Emax) maturation model demonstrated an increase in oral clearance with age to reach 90% of its mature level by the age of 9 months. The liquid formulation bioavailability relative to the capsule was found to increase with age to reach 90% of its mature value by the age of 8 years. The CYP2B6-G516T polymorphism decreased oral clearance, while the MDR1-C3435T polymorphism demonstrated no effect.

UR - http://www.scopus.com/inward/record.url?scp=84891512871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891512871&partnerID=8YFLogxK

U2 - 10.1128/AAC.01738-13

DO - 10.1128/AAC.01738-13

M3 - Article

C2 - 24145522

AN - SCOPUS:84891512871

VL - 58

SP - 136

EP - 143

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -